Subtitle: Market Intelligence, Genomic Annotation, and High-Specificity Reagents for Fc Receptor Homology Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FCGR1B (pseudogene) and related Fc-gamma receptor drug discovery. As a pseudogene highly homologous to the functional FCGR1A (CD64), FCGR1B is critical for specificity counter-screening and genomic polymorphism studies. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Homolog Control) | FCGR1A ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. (Functional Homolog) |
View FCGR1A Products |
| Gene Delivery / Clone | FCGR1B Promise-ORF / Genomic Clone Sequence Verified for homology mapping and transcription studies. |
View FCGR1B Products |
| Validator | FCGR1B siRNA Set For specific transcript knockdown verification. |
View FCGR1B Products |
| Related Target A | FCGR1A Functional high-affinity IgG receptor (CD64). Primary therapeutic target. |
View FCGR1A Products |
| Related Target B | FCGR1CP Another related pseudogene for comprehensive off-target screening. |
View FCGR1CP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity with FCGR1A | Sequence Verified genomic clones and precise siRNA to distinguish functional vs. pseudogene transcripts. |
| Genomic Polymorphism Mapping | High-fidelity plasmid constructs ensuring exact sequence matching for genomic assays. |
| False Positives in CD64 Assays | Validated siRNA included for specificity checks and background reduction. |
Live FCGR1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
While FCGR1B (FCGR1BP) does not encode a functional Fc receptor, its extreme sequence homology to FCGR1A (CD64) makes it a critical consideration in the development of targeted immunotherapies. The race for precision biologics requires rigorous counter-screening to ensure therapeutic antibodies and nucleic acid drugs do not cross-react with pseudogene transcripts or genomic elements, which could lead to off-target effects or assay interference.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Anti-CD64) | Various Biopharma | Autoimmune, Oncology | Specificity Screening (Need strict discrimination between FCGR1A and FCGR1B sequences) |
| siRNA / ASO | Emerging Biotech | Inflammation | Off-target Validation (Need precise FCGR1B transcript controls) |
| Diagnostic Probes | Genomic Profilers | Genetic Typing | Polymorphism Assay (Need Sequence Verified clones) |